Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
110.50    0.00 (0.00%)
Bid:
109.00
Ask:
112.00
Spread: 3.00 (2.752%)
Market Cap: £66.48m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Transaction in Own Shares

3 Dec 2014 07:00

RNS Number : 6681Y
Intercede Group PLC
03 December 2014
Β 

Intercede Group plc

("Intercede", the "Company" or the "Group")

Transaction in Own Shares

Β 

The Company announces that, in accordance with the terms of its general authority to make market purchases of its own shares granted to it by shareholders of the Company on 17 September 2014 and following the announcement by the Company on 6 November 2014, the Company on 2 December 2014 acquired 20,000 ordinary shares of 1 pence each in the capital of the Company (the "Ordinary Shares") (the "Purchase"). The Purchase was made in the market for cash at a price of 163.50 pence per Ordinary Share. Following the Purchase, the Ordinary Shares will be held in treasury.

The Company advises that, following the Purchase, the Company's issued share capital is 48,735,005 Ordinary Shares (including 239,000 Ordinary Shares held as treasury shares). Therefore the Company's total number of Ordinary Shares with voting rights is 48,496,005.

The above figure of 48,496,005 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Β 

Enquiries:

Β 

Intercede Group plc Tel: 01455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

Β 

finnCap Ltd Tel: 020 7220 0500

Stuart Andrews, Corporate Finance

Joanna Weaving, Corporate Broking

Β 

Β 

About Intercede

Β 

Intercede is a software company specialising in identity and credential management with a global team of experts located in the US and UK.

Β 

Intercede's MyID software enables organisations to create and use trusted digital identities for employees, citizens and machines. This allows secure access to services, facilities, information and networks.

Β 

MyID meets the highest government standards yet is simple enough to be deployed onto consumer devices such as smart phones and tablets. Critically, MyID provides an easy, convenient and secure alternative to passwords.

Β 

Millions of identities are managed using MyID and Intercede has provided identity verification and management services to global customers for more than 20 years. MyID is a commercial off the shelf software product, designed and developed to be configurable so it can be embedded as the cornerstone of cyber security infrastructure for governments and corporations.

Β 

Customers trusting Intercede for secure digital identity include the US and UK governments and some of the world's largest corporations, telecommunications providers and information technology partners.

Β 

For more information visit www.intercede.com.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
POSLLFSDFALFIIS
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.